[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361898-105":59,"doc-detail-361898-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-two-tumor-treatment-strategies-effectiveness-of-ribosome-inactivating-proteins-and-mesenchymal-stem-cellsmsc-derived-extracellular-vesicles-in-cancer-treatment-abstract","Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment - abstract","","Cancer is a complex, heterogeneous disease that often requires multifaceted treatment strategies to achieve optimal outcomes. Due to limitations of single-agent therapies, especially against intricate signaling networks and treatment resistance, combinatory approaches are increasingly needed. The article proposes combining ribosome-inactivating proteins with mesenchymal stem cells or MSC-derived extracellular vesicles to target tumors, modulate the microenvironment, and potentially reduce systemic toxicity. It also highlights key challenges and calls for future validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-two-tumor-treatment-strategies-effectiveness-of-ribosome-inactivating-proteins-and-mesenchymal-stem-cellsmsc-derived-extracellular-vesicles-in-cancer-treatment-abstract/361898/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-two-tumor-treatment-strategies-effectiveness-of-ribosome-inactivating-proteins-and-mesenchymal-stem-cellsmsc-derived-extracellular-vesicles-in-cancer-treatment-abstract/361898.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What combination approach does the review propose for cancer treatment?","Question",{"text":112,"@type":113},"It proposes the simultaneous use of ribosome-inactivating proteins (RIPs) together with mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (EVs). The goal is to combine RIP cytotoxicity with MSC/EV delivery and microenvironment modulation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is there a need for combinatory cancer therapies instead of single-agent treatments?",{"text":117,"@type":113},"Single-agent therapies are limited by complex biological signaling networks and treatment resistance. Combination strategies are intended to improve effectiveness and achieve better therapeutic outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges must be addressed before this combination can be validated clinically?",{"text":121,"@type":113},"Key challenges include optimizing dosing protocols, addressing safety concerns, and ensuring efficient drug delivery. Future research and clinical trials are required to confirm viability as a cancer therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361898,1792165439,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","TYPE Review  \nPUBLISHED 13 May 2025  \nDOI 10.3389/fonc.2025.1533065  \nOPEN ACCESS  \nEDITED BY  \nBekir Cinar,  \nClark Atlanta University, United States  \nREVIEWED BY  \nFatemeh Talebian,  \nThe Ohio State University, United States Narendra Sankpal,  \nSaint Joseph Hospital Medical Center Phoenix, United States  \n*CORRESPONDENCE  \nMohammad Hossein Abdolmohammadi  \n [mh.abdolmohammadi@gmail.com](mh.abdolmohammadi@gmail.com)[ ](mh.abdolmohammadi@gmail.com)Faranak Fallahian  \n [faranak.fallahian@gmail.com](faranak.fallahian@gmail.com)[ ](faranak.fallahian@gmail.com)Hamed Afkhami  \n [hamedafkhami70@gmail.com](hamedafkhami70@gmail.com)[ ](hamedafkhami70@gmail.com)†These authors share ﬁrst authorship  \nRECEIVED 23 November 2024  \nACCEPTED 15 April 2025  \nPUBLISHED 13 May 2025  \nCITATION  \nMavaei M, Farokhi S, Youseﬁ MH, Fakouri A, Shadab A, Abdolmohammadi MH, Fallahian Fand Afkhami H (2025) Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment. Front. Oncol. 15:1533065 .  \ndoi: 10.3389/fonc.2025.1533065  \nCOPYRIGHT  \n© 2025 Mavaei, Farokhi, Youseﬁ, Fakouri, Shadab, Abdolmohammadi, Fallahian and Afkhami. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nExploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/ MSC derived extracellular vesicles in cancer treatment  \nMaryamosadat Mavaei 1,2†, Simin Farokhi 3†,  \nMohammad Hasan Youseﬁ4,5,6, Arshia Fakouri 3,  \nAlireza Shadab 7,8, Mohammad Hossein Abdolmohammadi 6*, Faranak Fallahian 6* and Hamed Afkhami 6,4,9,10*  \n1Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran,  \n2 Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran, 3Student Research Committee, USERN Ofﬁce, Lorestan University of Medical Sciences, Khorramabad, Iran, 4Student Research Committee, Qom University of Medical Sciences, Qom, Iran, 5 Department of Tissue Engineering and Applied Cell Sciences, School of Medicine, Qom University of Medical Sciences, Qom, Iran, 6Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran, 7 Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran, 8 Iran University of Medical Sciences, Deputy of Health, Tehran, Iran, 9 Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran, 10 Department of Medical Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran  \nCancer is a complex and heterogeneous disease that often requires multifaceted treatment strategies to achieve optimal therapeutic outcomes. Given the limitations of single-agent therapies, particularly in the face of intricate biological signaling networks and treatment resistance, there is a growing need for combinatory approaches. This article presents a novel hypothesis: the simultaneous use of ribosome-inactivating proteins (RIPs) and mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (EVs) in cancer treatment. RIPs, with their potent cytotoxic properties, can target tumor cells effectively, while MSCs, known for their tumor-homing abilities and regenerative potential, can serve as delivery vehicles, potentially enhancing the targeting precision and reducing the systemic toxicity of RIPs. This hypothesis explores the synergistic potential of combining these two therapeutic modalities, leveraging the advantages of both techniques to creat","cbCaiucJOIwe95Z3","https://ap.wps.com/l/cbCaiucJOIwe95Z3","pdf",7596959,25,"English","# Introduction\n## Cancer burden and need for advanced therapies\n## Rationale for combination strategies\n## Challenges and future directions","[{\"question\":\"What combination approach does the review propose for cancer treatment?\",\"answer\":\"It proposes the simultaneous use of ribosome-inactivating proteins (RIPs) together with mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (EVs). The goal is to combine RIP cytotoxicity with MSC/EV delivery and microenvironment modulation.\"},{\"question\":\"Why is there a need for combinatory cancer therapies instead of single-agent treatments?\",\"answer\":\"Single-agent therapies are limited by complex biological signaling networks and treatment resistance. Combination strategies are intended to improve effectiveness and achieve better therapeutic outcomes.\"},{\"question\":\"What challenges must be addressed before this combination can be validated clinically?\",\"answer\":\"Key challenges include optimizing dosing protocols, addressing safety concerns, and ensuring efficient drug delivery. Future research and clinical trials are required to confirm viability as a cancer therapy.\"}]","Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment - abstract | PDF",1790145928,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c6730afa1f74cd8a61d4093306345cd.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43a870081368889baf31684f751afd98.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79382b273b91f6cda125c7388c297cf0.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ce2300d947b1ed9a640139f0cd71d8d.webp",980,1385]